hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06388772 id: HJG-CZQH-QHRD106 briefTitle: Study to Assess PK, Safety and Tolerability Early in Healthy Subjects overallStatus: COMPLETED date: 2021-07-05 date: 2022-07-22 date: 2023-01-06 date: 2024-04-29 date: 2024-04-29 name: Changzhou Qianhong Bio-pharma Co., Ltd. class: INDUSTRY briefSummary: The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses. conditions: Acute Ischemic Stroke studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 74 type: ACTUAL name: QHRD106 Injection name: placebo measure: Safety as assessed by incidence, severity, and causality of adverse events measure: Plasma measurements of QHRD106 sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Nanjing Drum Tower Hospital city: Nanjing state: Jiangsu zip: 210008 country: China lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06388759 id: TQ05105-Ib-03 briefTitle: TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients overallStatus: ACTIVE_NOT_RECRUITING date: 2022-08-01 date: 2024-12 date: 2024-12 date: 2024-04-29 date: 2024-04-29 name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. class: INDUSTRY briefSummary: This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy of TQ05105 Tablets in patients with intermediate-risk and high-risk myelofibrosis. conditions: Myelofibrosis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 9 type: ACTUAL name: TQ05105 Tablets measure: Spleen volume reduction (SVR35)≥35% from baseline measure: Optimum effective rate measure: Onset time of splenic response measure: Duration of maintenance of spleen response (DoMSR) ≥35% reduction measure: Myeloproliferative neoplasm- Symptom Assessment Form- Total Symptom Score (MPN-SAF TSS) : ≥ 50% Reduction from Baseline measure: The total symptom score of MPN-SAF TSS decreased compared with baseline measure: Progression-free survival (PFS) measure: Leukemia free survival (LFS) measure: Overall Survival (OS) measure: Incidence of adverse events (AEs) measure: Severity of AEs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Anhui Provincial Hospital city: Hefei state: Anhui zip: 230001 country: China lat: 31.86389 lon: 117.28083 facility: The First Affiliated Hospital of Wannan Medical College city: Wuhu state: Anhui zip: 241001 country: China lat: 31.33728 lon: 118.37351 facility: Union Hospital Tongji College Huazhong University of Science And Technology city: Wuhan state: Hubei zip: 430071 country: China lat: 30.58333 lon: 114.26667 facility: The Affiliated Hospital of Xuzhou Medical University city: Xuzhou state: Jiangsu zip: 221000 country: China lat: 34.18045 lon: 117.15707 facility: The First Hospital of Jilin University city: Changchun state: Jilin zip: 130021 country: China lat: 43.88 lon: 125.32278 facility: Shanghai Sixth People's Hospital city: Shanghai state: Shanghai zip: 200233 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06388746 id: NKUA briefTitle: Arresting Carious Lesions With Minimal Intervention Techniques overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-06 date: 2025-12 date: 2024-04-29 date: 2024-04-29 name: National and Kapodistrian University of Athens class: OTHER briefSummary: A single-blinded randomized clinical trial with a split-mouth design that will assess the 12-month clinical and radiographic success of two minimally invasive treatment techniques, one using a chemo-mechanical caries removal agent and one using a caries arresting agent, for the treatment of deep caries in primary molars. conditions: Caries,Dental studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: BRIX3000® name: Riva Star Aqua, SDI Limited, Australia measure: clinical success measure: radiographic success measure: Longevity and the quality of the final restoration measure: Patient's acceptance sex: ALL minimumAge: 4 Years maximumAge: 8 Years stdAges: CHILD hasResults: False
nctId: NCT06388733 id: IVY P3-24-021 briefTitle: A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2027-12 date: 2028-03 date: 2024-04-29 date: 2024-04-29 name: Ivy Brain Tumor Center class: OTHER name: GlaxoSmithKline briefSummary: The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are:
* Complete a diary to record study medication conditions: Glioblastoma conditions: GBM conditions: Brain Neoplasms, Adult, Malignant conditions: Brain Tumor studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE maskingDescription: Blinded Independent Central Review is composed of independent radiologists and will be utilized to assess progression of disease count: 450 type: ESTIMATED name: Niraparib name: Temozolomide measure: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) measure: Overall survival measure: Overall response rate measure: Compare symptoms, function, and Health-related quality of life (HRQoL) and symptoms by EORTC QLQ-C30-item Core module (EORTC QLQ-C30) (Scores on a scale) measure: Compare symptoms, function, and Health-related quality of life (HRQoL) and symptoms by EORTC QLQ-BN20-item Core module (EORTC QLQ-BN20) (Scores on a scale) measure: Changes from baseline in neurocognitive function assessed by Hopkins Verbal Learning Test measure: Changes from baseline in neurocognitive function assessed by Controlled Oral Word Association measure: Changes from baseline in neurocognitive function assessed by Trail Making Test Parts A and B measure: Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) measure: Number of treatment discontinuations, dose interruptions, and dose reductions due to AEs, SAEs, or AESIs, changes in Karnofsky performance status, changes in clinical laboratory results, and vital sign measurements measure: Frequency and severity of symptomatic AEs based on PRO-CTCAE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06388720 id: NCC2024-0026 briefTitle: The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy acronym: IMGeS overallStatus: RECRUITING date: 2024-04-30 date: 2025-06-30 date: 2027-12-31 date: 2024-04-29 date: 2024-04-29 name: National Cancer Center, Korea class: OTHER_GOV briefSummary: The aim of this study is to evaluate the effectiveness and safety of mitomycin-c and gemcitabine sequential instillation in BCG unresponsive high risk non-muscle invasive bladder cancer patients. conditions: Bladder Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 82 type: ESTIMATED name: Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml measure: Recurrent free survival in sequential treatment group. measure: Progression free survival in sequential treatment group. measure: Cystectomy free survival in sequential treatment group. measure: cancer specific survival in sequential treatment group. measure: Overall survival in sequential treatment group. measure: Safety of sequential treatment. sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Center status: RECRUITING city: Goyang-si country: Korea, Republic of name: Ho Kyung Seo role: CONTACT phone: 82-31-920-1678 email: seohk@ncc.re.kr name: Ho Kyung Seo, MD role: PRINCIPAL_INVESTIGATOR name: Eui Hyun Jung, Ph.D role: SUB_INVESTIGATOR lat: 37.65639 lon: 126.835 hasResults: False
nctId: NCT06388707 id: NF-2022-01 briefTitle: A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2025-07-31 date: 2025-12-31 date: 2024-04-29 date: 2024-04-29 name: NaviFUS Corporation class: INDUSTRY name: NaviFUS US LLC briefSummary: This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with drug-resistant unilateral or bilateral temporal lobe epilepsy (DR-TLE). conditions: Drug Resistant Epilepsy conditions: Epilepsy studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: NaviFUS System measure: Adverse events (AEs) measure: Change from baseline in seizure frequency measure: Change from baseline in electroencephalography (EEG) epileptiform discharges measure: Days of seizure-free measure: Changes from baseline in Beck Anxiety Inventory (BAI) measure: Changes from baseline in Beck Depression Inventory (BDI-II) measure: Changes from baseline in Personal Impact of Epilepsy Scale (PIES) measure: Change from baseline in subjective seizure strength sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford University School of Medicine city: Palo Alto state: California zip: 94305 country: United States name: Robert Fisher, M.D., Ph.D. role: CONTACT lat: 37.44188 lon: -122.14302 facility: Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02115 country: United States name: Ellen Bubrick, M.D. role: CONTACT lat: 42.35843 lon: -71.05977 facility: University of Virginia School of Medicine city: Charlottesville state: Virginia zip: 22903 country: United States name: Nathan Fountain, M.D. role: CONTACT lat: 38.02931 lon: -78.47668 hasResults: False
nctId: NCT06388694 id: RDO KPNC 24-056 briefTitle: Pharmacist Management of Attention Deficit Hyperactivity Disorder Medication Refill Requests overallStatus: NOT_YET_RECRUITING date: 2024-05-02 date: 2024-06-28 date: 2024-07-31 date: 2024-04-29 date: 2024-04-29 name: Kaiser Permanente class: OTHER briefSummary: This cluster randomized trial will compare pharmacist management of secure message requests for refills of attention deficit hyperactivity medications with primary care physician management regarding quality of care, timeliness of service, and parent care experience. conditions: Attention-deficit Hyperactivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: INVESTIGATOR count: 315 type: ESTIMATED name: Pharmacist Care name: Primary Care Physician Care measure: Percentage of participants appropriately referred for a follow-up weight check measure: Timeliness of care measure: Parent perception of effectiveness of care sex: ALL minimumAge: 2 Years maximumAge: 17 Years stdAges: CHILD facility: Kaiser Permanente Northern California city: Oakland state: California zip: 94612 country: United States lat: 37.80437 lon: -122.2708 hasResults: False
nctId: NCT06388681 id: HMKU-KMY-SA-02 briefTitle: Stress Ball Use in Patients Undergoing Coronary Angiography overallStatus: RECRUITING date: 2024-04-24 date: 2024-04-26 date: 2024-06-26 date: 2024-04-29 date: 2024-04-29 name: Mustafa Kemal University class: OTHER briefSummary: One of the nonpharmacologic interventions included in the NIC-Nursing Interventions Classification is the use of stress balls. Stress balls are one of the cognitive distraction methods used especially in reducing pain and increasing the comfort level of patients. On the other hand, there are studies showing that stress balls have a positive effect not only on pain but also on vital signs, anxiety and comfort level of the patient. conditions: Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 72 type: ESTIMATED name: The Effect of Stress Ball Use on Immobilization Comfort, Pain Level and Vital Signs in Patients Undergoing Coronary Angiography measure: Patient Identifying Information Form measure: Immobilization Comfort Scale measure: Visual Benchmarking Scale measure: Vital Signs Monitoring Form sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hatay Mustafa Kemal University status: RECRUITING city: Hatay country: Turkey name: SÜMEYYE AKÇOBAN role: CONTACT lat: 38.40227 lon: 27.10486 hasResults: False
nctId: NCT06388668 id: ICM 2025-3428 briefTitle: Lipid Testing After Myocardial Infarction at the Montreal Heart Institute overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-07 date: 2025-09 date: 2024-04-29 date: 2024-04-29 name: Montreal Heart Institute class: OTHER name: Novartis Pharmaceuticals briefSummary: Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization.
Thereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge. conditions: Dyslipidemias conditions: Lipid Testing conditions: Myocardial Infarction studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Lipid panel measure: Variation in LDL measure: Variation in non-HDL and apoB measure: Evaluation of intensification threshold measure: Repeat lipid panel after discharge measure: Evaluation of intensification threshold after discharge sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Montreal Heart Institute city: Montréal state: Quebec zip: H1T 1C8 country: Canada name: Guillaume Marquis-Gravel, MD, MSc role: CONTACT phone: (514) 376-3330 email: guillaume.marquis.gravel@umontreal.ca name: Guillaume Marquis-Gravel, MD, MSc role: PRINCIPAL_INVESTIGATOR name: Jean Grégoire, MD role: SUB_INVESTIGATOR name: François Simard, MD role: SUB_INVESTIGATOR name: Rafaël Monet-Alarcia, MD role: SUB_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06388655 id: MDCR-19-007 briefTitle: The Effect of the Mobile EEG-Neurofeedback in Healthy Child and Adolescent overallStatus: COMPLETED date: 2019-06-10 date: 2022-06-30 date: 2022-06-30 date: 2024-04-29 date: 2024-04-29 name: Daegu Catholic University Medical Center class: OTHER briefSummary: The objective of this study was to ascertain the therapeutic impact of mobile neurofeedback (MNF) in neurotypical children when compared to sham MNF. Clinical assessments were conducted both before and after the MNF intervention, and the effectiveness of the intervention was to be validated through these evaluations. conditions: Internet Addiction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 61 type: ACTUAL name: mobile neurofeedback name: sham mobile neurofeedback measure: Comparisons of the means of children's self-scale variables measure: Comparisons of the means of parents' self-scale variables : Beck Depression Inventory-II (BDI-II) measure: Comparisons of the means of parents' self-scale variables : Beck Anxiety Inventory (BAI) measure: Comparisons of the means of children's K-WISC-IV(Korean Wechsler Intelligence Scale for Children-IV) measure: Comparisons of the means of children's Stroop measure: Comparisons of the means of children's ATA(Advanced Test of Attention) measure: Comparisons of the means of children's CCTT(Children's Color Trails Test) sex: ALL minimumAge: 8 Years maximumAge: 15 Years stdAges: CHILD facility: Daegu Catholic University Medical Center city: Daegu state: Nam-gu zip: 42471 country: Korea, Republic of lat: 35.87028 lon: 128.59111 hasResults: False
nctId: NCT06388642 id: CUV052 briefTitle: Pharmacokinetics of Afamelanotide in EPP Patients overallStatus: RECRUITING date: 2024-03-07 date: 2024-07-01 date: 2024-10-01 date: 2024-04-29 date: 2024-04-29 name: Clinuvel Europe Limited class: INDUSTRY briefSummary: The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamelanotide in adolescent and adult EPP patients. conditions: Erythropoietic Protoporphyria studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 28 type: ESTIMATED name: Afamelanotide 16mg implant measure: Cmax (maximum Plasma Concentration) measure: AUC(0-t) (area under the curve from administration to last observed concentration at time t) measure: AUC(0-∞) (area under the curve extrapolated to infinite time) sex: ALL minimumAge: 12 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus Medical Center status: RECRUITING city: Rotterdam country: Netherlands name: Erasmus Medical Centre role: CONTACT lat: 51.9225 lon: 4.47917 hasResults: False
nctId: NCT06388629 id: M064-066 Rev 00 briefTitle: Epicardial Access Study With Rook acronym: EASY-R overallStatus: RECRUITING date: 2023-12-17 date: 2024-05 date: 2024-05 date: 2024-04-29 date: 2024-04-29 name: Circa Scientific, Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to test how how effective the Circa Scientific Rook® Epicardial Access Kit is at gaining guidewire access to the outside surface of the heart (epicardium). In addition the safety of the device will be compared to the available data for alternative methods of epicardial access.
Participants will receive treatment with the subject device during the course of a typical epicardial electrophysiology procedure. conditions: Arrythmia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Prospective, non-randomized primaryPurpose: OTHER masking: NONE count: 40 type: ESTIMATED name: Rook Epicardial Access Kit measure: Successful Epicardial Access measure: Speed of Access measure: Rate of Use Errors measure: Rate of Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Na Homolce Hospital status: RECRUITING city: Prague zip: 15030 country: Czechia name: Petr Neuzil, MD, PhD role: CONTACT phone: +420257272211 lat: 50.08804 lon: 14.42076 hasResults: False
nctId: NCT06388616 id: D6402C00013 briefTitle: Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone overallStatus: NOT_YET_RECRUITING date: 2024-05-02 date: 2024-11-15 date: 2024-11-15 date: 2024-04-29 date: 2024-04-29 name: AstraZeneca class: INDUSTRY briefSummary: This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of balcinrenone in patients with mild and moderate hepatic impairment in comparison to a matched healthy control group. conditions: Hepatic Impairment studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Three cohorts (two hepatic impairment cohorts and controls with normal hepatic function) will be enrolled into this study.
* Cohort 3 will enroll 8-12 healthy participants matched on a group level regarding age, BMI and sex primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Balcinrenone measure: Area under plasma concentration-time curve from time zero to the last measurable concentration (AUClast) measure: Area under plasma concentration-time curve from zero to infinity (AUCinf) measure: Maximum observed plasma concentration (Cmax) measure: AEs and SAEs up to the follow-up telephone call (Day 10 [± 3 days]) measure: Number of participants with abnormal Vital signs, abnormal ECGs, and abnormal physical examination findings measure: Number of participants with abnormal laboratory tests results sex: ALL minimumAge: 18 Years maximumAge: 79 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site city: Hialeah state: Florida zip: 33014 country: United States lat: 25.8576 lon: -80.27811 facility: Research Site city: Orlando state: Florida zip: 32809 country: United States lat: 28.53834 lon: -81.37924 facility: Research Site city: San Antonio state: Texas zip: 78215 country: United States lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06388603 id: DFORCT012023 briefTitle: RCT on Bioactive Glass S53P4 in Diabetic Foot Osteomyelitis in the Forefoot (DFORCT) acronym: DFORCT overallStatus: RECRUITING date: 2024-03-21 date: 2026-09-30 date: 2026-12-30 date: 2024-04-29 date: 2024-04-29 name: ASST Ovest Milanese class: OTHER name: Hippocrates Research name: Bonalive Biomaterials Ltd briefSummary: The Study will be a prospective multicenter randomized trial, focused on the management of acute and chronic Osteomilytis in Diabetic Foot patients. The aim of this Study will be to compare the effectiveness and safety of S53P4 bioactive glass, medical device class III used as per its CE mark indication and Instruction For Use, in the surgical management of OM in the forefoot performed as per local surgical standard of care, in the same indications in a group of Diabetic Foot patients admitted in highly specialized dedicated centers.
nctId: NCT06388590 id: MOMMC.2024.0029 briefTitle: Acupuncture for Chronic Pelvic Pain overallStatus: RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-04-29 date: 2024-04-29 name: David Moss class: FED briefSummary: The objective of this study is to determine if alternative pain management strategies, namely acupuncture, may help reduce intensity of female pelvic pain compared to other pain control modalities. This research study will focus specifically on the Dragon's protocol of acupuncture which will seek to alleviate chronic non-endometriosis pelvic pain for women both with and without a history of sexual assault.